Today: 2 July 2026
Browse Category

NYSE:LLY 10 September 2025 - 24 October 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Eli Lilly has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1ts2.techts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rallyts2.tech. By Oct. 23, LLY was trading near $818tradingview.com, solidly above its pre-September levels. Overall, the stock is up roughly 6% year-to-date, about matching the S&P 500 health-care indextradingview.com. Mid-October brought volatility. On Oct. 16, U.S. President Trump vowed to slash the price of Ozempic to about $150/monthts2.tech. Investors worried the measure could spill over to all GLP-1 treatments. Lilly – which sells similar drugs – saw its shares fall roughly 4% in sympathyts2.tech. The stock, which closed around $819 on Oct. 16, dipped into the high-$700s the following dayts2.tech. The episode underscored a new risk: while demand for weight-loss drugs is roaring, potential price controls or reimbursements remain a wild card.
23 October 2025
··
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market tradingreuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor namesreuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset Management, observing that even earnings surprises aren’t moving markets much in this wait-and-see environmentreuters.com. On the positive side, a string of solid earnings from traditional industries is boosting the Dow and S&P 500. Yesterday, heavyweights like Coca-Cola and 3M smashed expectations and hiked forecasts, sparking big stock popsreuters.com. General Motors likewise surged 14.9% after lifting its outlook amid easing tariff concernsreuters.com. These results show resilience in consumer spending and manufacturing. In fact, 87% of companies reporting so far have beaten forecastsreuters.com – a trend that has analysts projecting overall Q3 earnings growth near 9.2% year-on-yearreuters.com, the strongest in many quarters. Early earnings “provide stock investors with relief at
22 October 2025
···········
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping shift its Zacks Rank to #2. The sharp Monday jump may have been fueled by momentum traders reacting to these technicals and upbeat analyst commentary, as well as broader sector tailwinds. Notably, Beam’s Monday spike coincided with strength in gene-editing peers. Rival Intellia Therapeutics – whose CRISPR-based therapy posted remarkable Phase 1 results – has seen its stock soar in recent weeksts2.tech. Intellia shares are up over 70% in the past month and ~81% year-to-datefinviz.com after it reported that a one-time dose of its ATTR amyloidosis treatment led to a 92% reduction in a disease protein at 24 monthsts2.techts2.tech. Meanwhile, CRISPR Therapeutics, which co-developed the newly
20 October 2025
·····
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points on the dayreuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high set earlier this month, and is up roughly 15–17% for the year to datets2.tech – a strong performance reflecting 2025’s bullish momentum. Volatility made a comeback in recent days. The CBOE Volatility Index, Wall Street’s “fear index,” briefly spiked to around 29, a level not seen since April, before easing back to ~20 by week’s endts2.tech. That intraday surge in volatility underscores investors’ fragile sentiment: after a long stretch of calm, markets are suddenly confronting a confluence of risks. “The market is becoming more volatile, but it’s also coming off of a very non-volatile period,” explained Michael Reynolds of Glenmede, noting that with stock valuations at full levels, any new shock can jolt marketsreuters.comreuters.com. Indeed, traders rushed into protective options this week – bets that would pay out if the VIX jumps into the 40s – reflecting rising
18 October 2025
·········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example, one study in late September suggested GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk, adding to the buzz around Lilly’s pipelinets2.tech. However, mid-October brought a dose of volatility. On Oct. 16, President Trump publicly vowed to slash the cost of Ozempic – the popular GLP-1 drug made by Novo Nordisk – “from around $1,000 a month to $150”reuters.com. He dubbed it “the fat loss drug” and said price cuts would come “pretty fast”stocktwits.com. The comments, implying government-negotiated price reductions ahead, rattled the whole weight-loss drug sector. Novo Nordisk’s stock slid ~6% on the news, and Lilly’s shares fell roughly 4% in sympathy as investors braced for potential pricing
17 October 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

Eli Lilly and Company has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro and Zepbound have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highsmarketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street. After an extraordinary rally in late September 2025, LLY opened at $840.46 on 6 Oct 2025 and closed $839.87 on 3 Octmarketbeat.com, representing a roughly 15 % gain over the prior week. The 52‑week range was approximately $623.78–$937marketbeat.com, and the 50‑day and 200‑day moving averages were $734.60 and $765.44 respectivelymarketbeat.com. MarketBeat lists Lilly’s market capitalization at $795.46 billion and a P/E ratio of 54.93, reflecting investor expectation of sustained high growthmarketbeat.com. The company carries a debt‑to‑equity ratio of 1.86 and pays a modest dividend with a payout ratio around 36 %directorstalkinterviews.com.
6 October 2025
·
Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Wall Street extended its rally in the face of political gridlock. Last week, the S&P 500 and Dow each rose ~1.1%, and the Nasdaq gained 1.3%, with the S&P and Dow closing at record highs on Friday reuters.com. Monday’s trading opened on a strong note as well – S&P 500 futures were up about 0.3% early in the day, on track to add to those gains reuters.com. “It certainly feels like momentum is on the side of investors over the last few days,” said Mona Mahajan, head of investment strategy at Edward Jones reuters.com. She noted that traders have been increasingly betting on Federal Reserve rate cuts as economic data softens, even with Washington in disarray. The ongoing government shutdown, now past the one-week mark, has not derailed bullish sentiment so far. Indeed, investors largely “look past government shutdowns” since short standoffs historically have minimal market impact, according to Anthony Saglimbene, chief market strategist at Ameriprise Financial reuters.com. Volatility remained contained – the modest 0.01% uptick in the S&P 500 on Friday was enough for a new peak reuters.com. The Dow Jones Industrial Average climbed 0.5% to a record 46,519.72, while the Nasdaq Composite dipped 0.3% under pressure from tech
6 October 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

OpenAI vs. Musk’s xAI – legal battle heats up: The Silicon Valley rivalry between Elon Musk and OpenAI turned into open warfare in court. Musk’s AI startup xAI sued OpenAI, accusing it of poaching staff to steal trade secrets related to xAI’s Grok chatbot. This week OpenAI hit back, asking a judge to dismiss the suit and blasting it as part of Musk’s “ongoing harassment” of the company reuters.com. OpenAI’s filing argued that “talented xAI employees are leaving in droves” under Musk and have every right to join OpenAI reuters.com. Musk, a co-founder turned critic of OpenAI, claims xAI’s tech is more advanced than ChatGPT and that OpenAI conspired with Apple to suppress rivals – allegations both Apple and OpenAI deny reuters.com. “The truth is that xAI is hemorrhaging talent to other competitors, including OpenAI,” the filing stated bluntly reuters.com. The feud has become a high-profile drama amid the red-hot AI talent race, with dueling lawsuits reflecting the skyrocketing stakes in generative AI. As one industry commentator put it, this is “CEO-speak for ‘We’re pawns in a digital Cold War’” reuters.com – the AI war is as much personal as technological. Anthropic’s new cyber-defender AI: Amid the AI frenzy, startup
6 October 2025
··········
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com. Analysts are watching October closely. Goldman Sachs equity strategist John Marshall warned that the unusually strong September rally may give way to volatility: “Using history as a guide, we expect global equity volatility to increase in October,” he said webull.com webull.com, noting October is typically the year’s most eventful month. In short, strategists say October could be a “gauntlet” that tests this stock-market momentum webull.com webull.com.
2 October 2025
······
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com.
1 October 2025
·····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Fed policy: The Fed’s Sept. 17 decision to cut rates was driven by slowing growth and job gains, though inflation has crept up federalreserve.gov. Fed Chair Powell and colleagues signaled further cuts ahead, but warned that inflation upside risks remain high federalreserve.gov reuters.com. Fed Vice Chair Bowman urged a commitment to cuts to shore up jobs reuters.com, while a strategist noted Powell was dovish but noncommittal on timing reuters.com. Bank stocks: Regional banks held mixed news. First Horizon was downgraded by one analyst firm, while other analysts actually raised targets on FHN marketbeat.com. Insiders have been trimming positions marketbeat.com, adding to caution in the regional-banking sector. Overall, bank indices were modestly down on Sept 23 amid profit-taking reuters.com.
28 September 2025
·············
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Key Facts: Nvidia–OpenAI Partnership: Nvidia announced a landmark collaboration with OpenAI to deploy at least 10 gigawatts of AI computing power. Under the plan, Nvidia will invest up to $100 billion as each gigawatt of NVIDIA systems is deployed nvidianews.nvidia.com. The first 1 GW is slated for late 2026 on Nvidia’s new “Vera Rubin” supercomputer. CEO Jensen Huang said this marks “the next leap forward — deploying 10 gigawatts to power the next era of intelligence” nvidianews.nvidia.com. OpenAI’s Sam Altman emphasized that “everything starts with compute,” and the new chips will fuel AI breakthroughs. This deal comes amid massive demand for AI chips – Nvidia will continue to serve all customers, but the investment ties OpenAI and Nvidia closely together nvidianews.nvidia.com nvidianews.nvidia.com.
28 September 2025
·········
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Key Facts: After charging to all-time highs on Monday, U.S. tech stocks hit some turbulence to end the week. The Nasdaq Composite Index gained +0.44% on Friday to close around 22,484 reuters.com, helped by a relief rally on in-line inflation data. That advance broke a three-day losing streak for stocks latimes.com. Even so, the Nasdaq Composite fell ~0.7% for the week, while the S&P 500 and Dow also logged modest weekly declines reuters.com reuters.com. This marked the end of a three-week run of gains for the Nasdaq and S&P reuters.com. The Nasdaq-100 index of top-tier tech shares showed a similar pattern – rebounding Friday but finishing slightly lower week-over-week.
27 September 2025
··········
Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Flags and tickers on the NYSE trading floor in New York City, reflecting a week of shifting market sentiment. U.S. stocks rallied into the weekend after overcoming mid-week losses reuters.com reuters.com. Wall Street finished the week with a relief rally, snapping a multi-session losing streak. On Friday, Sept. 26, the Dow Jones Industrial Average jumped about 300 points to 46,247, the S&P 500 gained +0.6% to 6,644, and the Nasdaq Composite rose +0.4% to 22,484 reuters.com. This rebound followed three straight down sessions through Thursday, which had left the major indexes in the red for the week. Thanks to Friday’s climb, the weekly losses were pared to around –0.2% to –0.7% reuters.com – ending a three-week run of gains but preserving most of the market’s recent upside momentum.
27 September 2025
······
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m, core +0.2% m/m. Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print. Reuters “This should give some reassurances on the inflation side,” said Doug Beath of Wells Fargo Investment Institute. Reuters
26 September 2025
·······
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

AI Designs New Viruses: In a stunning demonstration of AI’s creative power, scientists announced they have used artificial intelligence to design the first-ever viruses from scratch. The AI wrote complete viral genomes for bacteriophages which were then synthesized in the lab nature.com. Several of these AI-generated phages successfully infected and killed E. coli bacteria that natural phages couldn’t attack nature.com. “This is the first time AI systems are able to write coherent genome-scale sequences,” said Stanford computational biologist Brian Hie, calling it a step toward “AI-generated life” nature.com. While still in preprint and not yet peer-reviewed, the breakthrough suggests AI could become a powerful tool for engineering new biomedical therapies nature.com nature.com. Researchers hope AI-designed phages might one day help fight antibiotic-resistant superbugs nature.com nature.com – showcasing a real-world payoff for AI in medicine. The work also raises biosafety questions, as wholly novel organisms can now be created digitally, underscoring the need for oversight as “the next step is AI-generated life,” in Hie’s words nature.com. AI in Healthcare at Scale: China has taken a leap in applying AI to public health management. A tech firm in Guangdong unveiled a vast AI-driven platform called “XingShi” to manage chronic diseases for millions
20 September 2025
·····
Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly 25–27 pounds lost for someone who began the trial at 220 lbs. Lower doses yielded smaller effects theguardian.com. Notably, around 18% of those on the top dose shed at least 20% of their body weight, a dramatic transformation in line with what injections have achieved for some patients theguardian.com. More than half the high-dose group lost at least 10% of body weight fiercebiotech.com, indicating meaningful benefits for many.
17 September 2025
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will include over 200,000 square feet of production space Virginiabusiness, equipped with cutting-edge technologies like machine learning, artificial intelligence, and automation to ensure precision and efficiency Prnewswire. Construction is beginning immediately and expected to take about five years to fully complete Washingtonpost – a timeline Lilly hopes to beat if possible, according to CEO David “Dave” Ricks Virginiabusiness. Initial site work and permitting are starting within weeks, and Lilly aims to have the physical plant built in about three years, then undergo equipment validation and regulatory approvals Virginiabusiness. “The typical timeline…is five years…so we’d like to beat that,” Ricks said, noting Lilly is working with federal regulators to speed up
16 September 2025
·······
Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

One of the week’s most striking research breakthroughs came from Stony Brook University, where scientists unveiled an AI system called SeeMe that can detect “covert consciousness” in patients with acute brain injuries news.stonybrook.edu. In a study of 37 coma patients, SeeMe’s computer vision algorithms analyzed subtle, involuntary facial muscle movements in response to verbal commands, movements so slight they’re invisible to the naked eye news.stonybrook.edu. Remarkably, the tool identified signs of awareness 4–8 days earlier than standard bedside neurological exams news.stonybrook.edu news.stonybrook.edu. Lead researcher Dr. Sima Mofakham explained the high stakes: up to 25% of patients labeled “unresponsive” may actually be conscious but unable to show it news.stonybrook.edu. “We developed SeeMe to fill the gap between what patients can do and what clinicians can observe,” she said, noting that just because a patient can’t move or speak “doesn’t mean they aren’t conscious. Our tool uncovers those hidden physical efforts” to signal awareness news.stonybrook.edu. In the study, patients who showed early responses picked up by SeeMe were significantly more likely to eventually wake up and recover better function news.stonybrook.edu. Clinicians say this AI-driven diagnostic could prevent premature withdrawal of care and ensure rehabilitative therapy isn’t denied to patients who still have
10 September 2025
·····
1 … 10 11 12 13

Stock Market Today

  • Cramer’s Top 10: Jobs Miss, Upgrades for Palantir and Airlines, OpenAI’s Government Plan
    July 2, 2026, 9:20 AM EDT. Jim Cramer's July 2 watchlist points to a lighter-than-forecast June jobs report-nonfarm payrolls up just 57,000, well below the 115,000 expected. That pushed Treasury yields lower and futures up. OpenAI is reportedly offering the U.S. government a 5% stake to let it in on AI gains. Palantir saw DA Davidson boost the stock to buy, setting a target for 40% upside. Nvidia is rolling out a model where AI startups get compute power in exchange for a piece of revenue. Meta laid out fresh plans for cloud AI. Honeywell Aerospace, Delta, and United picked up upgrades as supply and fuel costs improved. DuPont's price target saw a small bump.
Go toTop